| 证券代码 | GNMK.O |
| 证券名称 | GenMark Diagnostics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2010-05-28 |
| 首发价格(元) | 6 USD |
| 首发数量(股) | 4600000 |
| 首发募资额(元) | 27,600,000.00 USD |
| 首发主承销商 | Piper Jaffray & Co. |
| 货币单位 | USD |
| 公司名称 | GenMark Diagnostics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 5964 La Place Court, Carlsbad, California, USA |
| 成立日期 | 2010-02 |
| 董事会主席 | - |
| 公司属地 | United States 美国 |
| 公司网址 | www.genmarkdx.com |
| 电话 | +1 (760) 448-4300 |
| 传真 | +1 (760) 448-4301 |
| 公司简介 | GenMark Diagnostics, Inc. is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor(R) detection technology, GenMark’s eSensor XT-8(R) system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. The eSensor detection technology is also incorporated into GenMark’s True Sample-to-Answer System, ePlex(R). |